1. Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan
- Author
-
Emi, Takashita, Hiroko, Morita, Shiho, Nagata, Masayuki, Shirakura, Seiichiro, Fujisaki, Hideka, Miura, Ikuyo, Takayama, Tomoko, Arita, Yasushi, Suzuki, Masaoki, Yamaoka, Taichiro, Tanikawa, Ryota, Tsunekuni, Junki, Mine, Saki, Sakuma, Yuko, Uchida, Akihiro, Shibata, Mari, Iwanaka, Noriko, Kishida, Kazuya, Nakamura, Tsutomu, Kageyama, Shinji, Watanabe, and Hideki, Hasegawa
- Subjects
Microbiology (medical) ,Influenza A Virus, H5N1 Subtype ,Influenza A Virus, H7N7 Subtype ,Neuraminidase ,DNA-Directed RNA Polymerases ,General Medicine ,Influenza A Virus, H7N9 Subtype ,Antiviral Agents ,Poultry ,Oseltamivir ,Infectious Diseases ,Japan ,Influenza in Birds ,Drug Resistance, Viral ,Influenza, Human ,Influenza A Virus, H9N2 Subtype ,Animals ,Humans ,Enzyme Inhibitors ,Influenza A Virus, H5N2 Subtype - Abstract
The circulation of avian influenza A viruses in poultry is a public health concern due to the potential transmissibility and severity of these viral infections. Monitoring the susceptibility of these viruses to antivirals is important for developing measures to strengthen the level of preparedness against influenza pandemics. However, drug susceptibility information on these viruses is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: an M2 inhibitor (amantadine), neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir) and RNA polymerase inhibitors (baloxavir and favipiravir). Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess phenotypic viral susceptibility to drugs have revealed that these avian influenza A viruses are susceptible to neuraminidase and RNA polymerase inhibitors. These results suggest that neuraminidase and RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans.
- Published
- 2022
- Full Text
- View/download PDF